Cargando…
Challenges in the discontinuation of chronic hepatitis B antiviral agents
Long-term antiviral treatment of chronic hepatitis B patients has been proven to be beneficial in reducing liver-related complications. However, lengthy periods of daily administration of medication have some inevitable drawbacks, including decreased medication adherence, increased cost of treatment...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473499/ https://www.ncbi.nlm.nih.gov/pubmed/34630873 http://dx.doi.org/10.4254/wjh.v13.i9.1042 |
_version_ | 1784575004857335808 |
---|---|
author | Kaewdech, Apichat Sripongpun, Pimsiri |
author_facet | Kaewdech, Apichat Sripongpun, Pimsiri |
author_sort | Kaewdech, Apichat |
collection | PubMed |
description | Long-term antiviral treatment of chronic hepatitis B patients has been proven to be beneficial in reducing liver-related complications. However, lengthy periods of daily administration of medication have some inevitable drawbacks, including decreased medication adherence, increased cost of treatment, and possible long-term side effects. Currently, discontinuation of antiviral agent has become the strategy of interest to many hepatologists, as it might alleviate the aforementioned drawbacks and increase the probability of achieving functional cure. This review focuses on the current evidence of the outcomes following stopping antiviral treatment and the factors associated with subsequent hepatitis B virus relapse, hepatitis B surface antigen clearance, and unmet needs. |
format | Online Article Text |
id | pubmed-8473499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-84734992021-10-08 Challenges in the discontinuation of chronic hepatitis B antiviral agents Kaewdech, Apichat Sripongpun, Pimsiri World J Hepatol Minireviews Long-term antiviral treatment of chronic hepatitis B patients has been proven to be beneficial in reducing liver-related complications. However, lengthy periods of daily administration of medication have some inevitable drawbacks, including decreased medication adherence, increased cost of treatment, and possible long-term side effects. Currently, discontinuation of antiviral agent has become the strategy of interest to many hepatologists, as it might alleviate the aforementioned drawbacks and increase the probability of achieving functional cure. This review focuses on the current evidence of the outcomes following stopping antiviral treatment and the factors associated with subsequent hepatitis B virus relapse, hepatitis B surface antigen clearance, and unmet needs. Baishideng Publishing Group Inc 2021-09-27 2021-09-27 /pmc/articles/PMC8473499/ /pubmed/34630873 http://dx.doi.org/10.4254/wjh.v13.i9.1042 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Kaewdech, Apichat Sripongpun, Pimsiri Challenges in the discontinuation of chronic hepatitis B antiviral agents |
title | Challenges in the discontinuation of chronic hepatitis B antiviral agents |
title_full | Challenges in the discontinuation of chronic hepatitis B antiviral agents |
title_fullStr | Challenges in the discontinuation of chronic hepatitis B antiviral agents |
title_full_unstemmed | Challenges in the discontinuation of chronic hepatitis B antiviral agents |
title_short | Challenges in the discontinuation of chronic hepatitis B antiviral agents |
title_sort | challenges in the discontinuation of chronic hepatitis b antiviral agents |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473499/ https://www.ncbi.nlm.nih.gov/pubmed/34630873 http://dx.doi.org/10.4254/wjh.v13.i9.1042 |
work_keys_str_mv | AT kaewdechapichat challengesinthediscontinuationofchronichepatitisbantiviralagents AT sripongpunpimsiri challengesinthediscontinuationofchronichepatitisbantiviralagents |